Gene editing for immune cell therapies.

Area of Science:

• Immunology
• Genetics
• Oncology

Background:

• Chimeric antigen receptor (CAR) T cell therapies targeting CD19 have achieved significant clinical success in B cell malignancies.
• The field of immune cell engineering is rapidly advancing to address challenges like antigen selection, tumor microenvironment, and therapy logistics.

Purpose of the Study:

• To review innovations in immune cell engineering for cancer therapy.
• To discuss the application of these technologies to various immune cells and diseases.
• To highlight preclinical and early clinical findings of next-generation cell therapies.

Main Methods:

• Review of current literature and clinical trial data on engineered cell therapies.
• Discussion of advancements in CAR design, gene transfer, and gene-editing technologies.
• Exploration of applications beyond T cells, including NK cells, hematopoietic stem cells, and iPSCs.

Main Results:

• Engineered T cells demonstrate sophisticated sensing circuits and synthetic functionalities.
• Development of off-the-shelf, universal cellular products is progressing.
• Next-generation approaches are showing promising early translational results in clinical trials.

Conclusions:

• Engineered cell therapies hold significant potential to transform the treatment of various cancers and other diseases.
• Continued innovation in gene-modified and gene-edited cell therapies is expected.
• The application of these technologies to diverse cell types broadens therapeutic possibilities.